Battle Over Dementia Drug Swap Has Big Stakes For Drugmakers, Consumers
A court ruling about Actavis’s strategy to switch consumers from its top-selling dementia drug, which will lose patent protection this summer, to a newer, patent-protected drug, may define how far drugmakers can go to protect profits from generic rivals.